Release Time：2024-09-10 08:49:22Source：Eyebright
From September 6 to 10, 2024, Eyebright Medical has participated in the 42nd European Society of Cataract and Refractive Surgeons Congress (ESCRS) showcased its range of self-developed products in cataract surgery, myopia management, and consumer vision care, receiving significant recognition in the global market and reinforcing its commitment to excellence in ophthalmic care. The grand event had attracted over 15,000 participants and facilitating valuable exchanges among leading ophthalmic experts.
Eyebright Medical’s star products, including the monofocal EDOF intraocular lens, multifocal EDOF intraocular lens, and preloaded high-order aspheric intraocular lens series, garnered significant attention at the ESCRS Congress, attracting agents and doctors from around the world eager to learn about and experience these cutting-edge innovations.
The monofocal EDOF lens enhances postoperative intermediate and near vision while minimizing visual disturbances, whereas the multifocal EDOF lens offers clear distance and near vision alongside functional intermediate vision, reducing adverse visual phenomena. Additionally, the preloaded intraocular lens features a streamlined one-step operation design that greatly improves surgical efficiency and safety. With corresponding Toric versions available, Eyebright Medical’s high-end intraocular lens series effectively meets the personalized selection needs for refractive cataract surgery.
ESCRS has always been an excellent opportunity to share the latest advancements in the field of ophthalmology, learn about innovative products, and connect with peers from around the world. This time, Eyebright Medical showcased its full range of self-developed products at ESCRS, gaining increased attention and recognition in the overseas market. Furthermore, it facilitated in-depth exchanges with international experts and scholars in the field of ophthalmology, discussing cutting-edge technologies and development directions, injecting new momentum into its progress toward becoming a leading international medical enterpris.
